市場調査レポート

商品コード

1747454

神経変性疾患の世界市場：適応症別、薬剤クラス別、流通チャネル別、地域別、機会、予測、2018年～2032年

Global Neurodegenerative Diseases Market Assessment, By Indication, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年06月13日
発行: Market Xcel - Markets and Data
ページ情報: 英文 226 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,800 698,016円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 6,000 872,520円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,500 1,236,070円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.42円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の神経変性疾患の市場規模は、2025年～2032年の予測期間中に7.51％のCAGRで拡大し、2024年の552億1,000万米ドルから2032年には985億4,000万米ドルに成長すると予測されています。世界の神経変性疾患は、人口の増加、研究開発への投資、治療薬の技術革新により急速な成長を遂げています。

神経変性疾患市場は、世界人口の高齢化が進み、アルツハイマー病やパーキンソン病が多発していることから、著しい成長を遂げています。この成長は、病気の症状を管理するだけでなく、病気そのものに介入するための新しいバイオマーカーや診断法の開発への投資が増加していることにも起因しています。さらに、新たな遺伝子技術やバイオマーカーを用いた精密医療への動きや、対症療法から疾患修飾療法への変化、神経変性疾患の早期段階をターゲットとする動きも、この分野の強い動向となっています。これらの疾患の発見と臨床開発における複雑さ（および薬剤開発コスト）という課題にもかかわらず、技術と革新、医学研究に対する政府と民間の継続的な投資、および重大なアンメット・メディカル・ニーズを有する新規市場の特定において、大きな機会が存在します。

さらに、2025年5月に神経変性疾患市場を支援するため、Sanofi S.A.は、神経変性疾患患者のための新規治療薬を開発する臨床段階のバイオテクノロジー企業であるVigil Neuroscience, Inc.の買収に踏み切ったことを発表しました。また、Sanofiの初期段階のパイプラインを強化し、経口低分子TREM2アゴニストであるVG-3927のアルツハイマー病を対象とした第2相臨床試験への参入を提供します。

当レポートでは、世界の神経変性疾患市場について調査し、市場の概要とともに、適応症別、薬剤クラス別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

市場規模分析と予測
市場シェア分析と予測
- 適応症別
  - アルツハイマー病
  - パーキンソン病
  - 筋萎縮性側索硬化症
  - ハンチントン病
  - その他
- 薬剤クラス別
  - N-メチル-D-アスパラギン酸（NMDA）受容体拮抗薬
  - コリンエステラーゼ阻害剤
  - ドーパミン作動薬
  - 免疫調節薬
  - その他
- 流通チャネル別
  - 病院薬局
  - 小売薬局
  - オンライン薬局
  - その他
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
2024年の市場マップ分析

第6章北米の神経変性疾患市場の見通し、2018年～2032年

市場規模分析と予測
市場シェア分析と予測
国別市場評価
- 米国
- カナダ
- メキシコ

第7章欧州の神経変性疾患市場の見通し、2018年～2032年

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第8章アジア太平洋の神経変性疾患市場の見通し、2018年～2032年

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第9章南米の神経変性疾患市場の見通し、2018年～2032年

ブラジル
アルゼンチン

第10章中東・アフリカの神経変性疾患市場の見通し、2018年～2032年

サウジアラビア
アラブ首長国連邦
南アフリカ

第11章需要供給分析

第12章バリューチェーン分析

第13章サプライチェーン分析

第14章ポーターのファイブフォース分析

第15章 PESTLE分析

第16章価格分析

第17章市場力学

市場の促進要因
市場の課題

第18章市場動向と発展

第19章規制枠組みとイノベーション

臨床試験
規制当局の承認

第20章特許の情勢

第21章ケーススタディ

第22章競合情勢

市場リーダートップ5の競合マトリックス
参入企業トップ5のSWOT分析
市場の主要企業トップ10の情勢
- AbbVie Inc.
- Novartis AG
- Merck & Co., Inc
- Biogen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Sanofi S.A
- GlaxoSmithKline PLC
- UCB S.A.
- H. Lundbeck A/S
- Boehringer Ingelheim International GmbH

第23章戦略的提言

第24章調査会社について・免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 2. Global Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 3. Global Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 4. Global Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 5. Global Neurodegenerative Disease Market Share (%), By Region, 2018-2032F
Figure 6. North America Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 7. North America Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 8. North America Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 9. North America Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 10. North America Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
Figure 11. United States Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 12. United States Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 13. United States Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 14. United States Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 15. Canada Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 16. Canada Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 17. Canada Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 18. Canada Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 19. Mexico Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 20. Mexico Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 21. Mexico Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 22. Mexico Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 23. Europe Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 24. Europe Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 25. Europe Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 26. Europe Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 27. Europe Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
Figure 28. Germany Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 29. Germany Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 30. Germany Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 31. Germany Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 32. France Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 33. France Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 34. France Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 35. France Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 36. Italy Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 37. Italy Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 38. Italy Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 39. Italy Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 40. United Kingdom Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 41. United Kingdom Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 42. United Kingdom Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 43. United Kingdom Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 44. Russia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 45. Russia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 46. Russia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 47. Russia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 48. Netherlands Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 49. Netherlands Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 50. Netherlands Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 51. Netherlands Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 52. Spain Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 53. Spain Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 54. Spain Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 55. Spain Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 56. Turkey Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 57. Turkey Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 58. Turkey Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 59. Turkey Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 60. Poland Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 61. Poland Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 62. Poland Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 63. Poland Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 64. South America Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 65. South America Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 66. South America Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 67. South America Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 68. South America Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
Figure 69. Brazil Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 70. Brazil Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 71. Brazil Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 72. Brazil Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 73. Argentina Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 74. Argentina Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 75. Argentina Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 76. Argentina Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 77. Asia-Pacific Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 78. Asia-Pacific Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 79. Asia-Pacific Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 80. Asia-Pacific Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 81. Asia-Pacific Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
Figure 82. India Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 83. India Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 84. India Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 85. India Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 86. China Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 87. China Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 88. China Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 89. China Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 90. Japan Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 91. Japan Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 92. Japan Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 93. Japan Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 94. Australia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 95. Australia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 96. Australia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 97. Australia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 98. Vietnam Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 99. Vietnam Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 100. Vietnam Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 101. Vietnam Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 102. South Korea Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 103. South Korea Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 104. South Korea Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 105. South Korea Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 106. Indonesia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 107. Indonesia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 108. Indonesia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 109. Indonesia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 110. Philippines Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 111. Philippines Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 112. Philippines Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 113. Philippines Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 114. Middle East & Africa Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 115. Middle East & Africa Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 116. Middle East & Africa Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 117. Middle East & Africa Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 118. Middle East & Africa Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
Figure 119. Saudi Arabia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 120. Saudi Arabia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 121. Saudi Arabia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 122. Saudi Arabia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 123. UAE Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 124. UAE Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 125. UAE Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 126. UAE Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 127. South Africa Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
Figure 128. South Africa Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
Figure 129. South Africa Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
Figure 130. South Africa Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
Figure 131. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 132. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Product Code: MX13333

Global neurodegenerative disease market is projected to witness a CAGR of 7.51% during the forecast period 2025-2032, growing from USD 55.21 billion in 2024 to USD 98.54 billion in 2032. The global neurodegenerative disease is experiencing rapid growth due to a growing population, investment in research and development, and innovation in therapeutic drugs.

The neurodegenerative disease market is undergoing significant growth, due to the increasing aging global population, leading to many instances of Alzheimer's and Parkinson's disease. The growth is also due to the increasing investment in developing new biomarkers or diagnostics to not only manage the symptoms of the disease but also to intervene on the disease itself. Additional strong trends in space are the move towards precision medicine with new genetic technologies or biomarkers, and the change from symptomatic therapies to disease-modifying therapies and targeting earlier stages of neurodegenerative disease. Despite the challenges of complexity (and drug development costs) in discovery and clinical development of these diseases, there are significant opportunities in technology and innovation, continuing government and private investments in medical research, and identifying new markets that have significant unmet medical needs.

Additionally, to support the neurodegenerative disease market in May 2025, Sanofi S.A. announced that enter into a transaction for Vigil Neuroscience, Inc., a clinical-stage biotechnology company that is publicly traded and develops novel therapies for people with neurodegenerative diseases. It also strengthens Sanofi's early-stage pipeline and provides entry into a phase 2 clinical study of VG-3927, an oral small-molecule TREM2 agonist, in Alzheimer's disease.

Increase in Population and Growing Awareness Support Market Expansion

The growing aging population and rising awareness concerning diseases are major drivers of the global market. As life expectancy increases, the risk of age-related diseases such as Alzheimer's and Parkinson's will ramp up demand for standard of care diagnostic tools, treatments, and long-term care post-diagnosis for an exponentially larger pool of patients. Significant research and development investments will emerge due to the combined effects of rising healthcare demand and the system's current overcapacity. The medical research funding will prioritize innovative disease-modifying treatments alongside advanced AI and digital health technologies. The increased public knowledge and efforts to detect neurodegenerative disorders sooner will generate greater market interest. A new generation of treatment models will develop which will deliver a better quality of life to vast populations dealing with these disorders. The new advancements will work toward creating medical solutions that can either reduce the rate of disease progression or completely stop its progression.

Additionally, to support aging populations who are affected by neurodegenerative disease, in March 2023, the Government of Canada announced it to invest USD 38.3 million in a research study to address the challenges of aging and brain health issues, including dementia, and provide quality of life for the aging population of Canada.

Rise in Investment in R&D Activities Boosts Market Demand

The market witnesses a rise in consumer demand as companies invest in research and development for the creation of new products. Organizations use research and development to detect unaddressed customer requirements and sometimes foresee upcoming market needs. Proper foresight plays an essential role because successful R&D work generates innovative solutions that customers enthusiastically adopt. Several types of innovation, including feature additions, performance enhancements, efficiency improvements, and brand-new functions, drive global market growth. The development of new product features enables companies to compete for customer choice. Companies conduct research and development work to enhance production processes, which helps them minimize manufacturing expenses. The cost savings resulting from better production processes permit companies to decrease their pricing to reach new customer groups. In addition, federations globally are announcing funds to address the rising demand and advancement in drug development.

For instance, in September 2023, the FDA announced that it has awarded over USD 16.9 million in funding over a next four-year period for important research through its Rare Neurodegenerative Disease Grant Program, including studies for amyotrophic lateral disease (ALS), and other rare neurodegenerative diseases, such as Niemann-Pick type C and myotonic dystrophy type 1.

Alzheimer's Diseases Holds Largest Global Neurodegenerative Disease Market Share

Alzheimer's Disease (AD) has the largest market share in neurodegenerative diseases, based primarily on the extent of its burden, with dementia being the most prevalent and common form, and the rapid growth of the aged population across the world. New disease-modifying therapies have brought about revolutionary market expansion through their ability to attack the root causes of diseases instead of basic symptoms. The growing burden of disease receives continuous research and development support, which drives advancements in drug development and diagnostic technology. The persistent dedication to research and development efforts keeps Alzheimer's disease at the forefront of medical institutions' focus for therapeutic and diagnostic solutions.

For instance, in December 2023, according to the Alzheimer's Association's report, about 6.7 million individuals aged 65 and older in the U.S. have Alzheimer's disease and estimates project to rise to 13.8 million by 2060.

North America Dominates Neurodegenerative Disease Market

North America has the dominant share of the neurodegenerative disease market due to its high prevalence, a well-established health care system, and an R&D commitment. Drug development leaders are in the United States, with Biogen (Alzheimer's), AbbVie (Parkinson's), and Ionis Pharmaceuticals (ALS) leading the innovation front. Other aspects of the region that promote growth are the upside in easy-to-access reimbursement from publicly funded insurance (Medicare) and private insurers, and an increasing aging population. North America also conducts significantly more clinical trials for screening and drugs for neurodegenerative disease therapies than other regions, which reduces the time to approval.

Additionally, to support health care infrastructure and clinical trial in March 2024

United State Congress approved a USD 100 million funding for National Institute of Health (NIH) to support Alzheimer's and dementia research for fiscal year 2024, and USD 34 million to support the BOLD Infrastructure Act an aspirational, bipartisan priority championed by the Alzheimer's Association and Alzheimer's Impact Movement (AIM). To receive such investment, scientists need to drive innovation and quality of treatment to prevent Alzheimer's.

Impact of U.S. Tariffs on the Global Neurodegenerative Disease Market

The U.S. tariffs will create substantial effects on the market for neurodegenerative diseases because they will boost expenses and disrupt pharmaceutical and medical equipment distribution networks. Cough suppressants and Alzheimer's and Parkinson's, and ALS medications depend on active pharmaceutical ingredients that enter the country through imports. Tariffs imposed on these items would result in higher production expenses, which would indirectly cause patients to pay increased costs for their treatments. Patients could experience treatment delays because of supply chain problems. The imposition of potential retaliatory tariffs would result in decreased exports of U.S.-made drugs to foreign markets, which would further burden the sector. The implementation of tariffs would place financial pressure on smaller biotech firms, which currently serve as the main drivers of innovation within the industry. The financial constraints would lead to decreased research in new drugs and result in delayed development of economically feasible treatment methods.

Key Players Landscape and Outlook

Continuous innovation characterizes the landscape of neurodegenerative disease globally, as companies are making substantial investments in research, pursuing strategic partnerships, and accelerating the launch of new products. Gene therapies and RNA-targeting drugs are a primary focus and will be major drivers of growth. The future looks bright, fueled by an aging global population and recent breakthroughs in neuroscience, along with increased investments in precision medicine, AI-assisted drug discovery, and diagnostics.

In January 2025, Eisai Co., Ltd. and Biogen, Inc. jointly announced that they received a grant from the U.S. Food and Drug Administration (FDA) approval for a supplemental Biologics License Application for lecanemab-irmb to maintain the dosing regimen of once every four weeks and offers a potentially more convenient treatment option for eligible patients.

In January 2024, AbbVie Inc. launched PRODUODOPA treatment for advanced Parkinson's, a disease with severe motor-like fluctuations and involuntary movement. It helps patients by extending the period when symptoms are well-controlled by other therapies.

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Neurodegenerative Diseases Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Indication
  - 5.2.1.1. Alzheimer's Disease
  - 5.2.1.2. Parkinson's Disease
  - 5.2.1.3. Amyotrophic Lateral Sclerosis
  - 5.2.1.4. Huntington's Disease
  - 5.2.1.5. Other Indications
- 5.2.2. By Drug Class
  - 5.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
  - 5.2.2.2. Cholinesterase Inhibitors
  - 5.2.2.3. Dopamine Agonists
  - 5.2.2.4. Immunomodulatory Drugs
  - 5.2.2.5. Other Drug Classes
- 5.2.3. By Distribution Channel
  - 5.2.3.1. Hospital Pharmacies
  - 5.2.3.2. Retail Pharmacies
  - 5.2.3.3. Online Pharmacies
  - 5.2.3.4. Others
- 5.2.4. By Region
  - 5.2.4.1. North America
  - 5.2.4.2. Europe
  - 5.2.4.3. Asia-Pacific
  - 5.2.4.4. South America
  - 5.2.4.5. Middle East and Africa
- 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
5.3. Market Map Analysis, 2024
- 5.3.1. By Indication
- 5.3.2. By Drug Class
- 5.3.3. By Distribution Channel
- 5.3.4. By Region

6. North America Neurodegenerative Diseases Market Outlook, 2018-2032F

6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
6.2. Market Share Analysis & Forecast
- 6.2.1. By Indication
  - 6.2.1.1. Alzheimer's Disease
  - 6.2.1.2. Parkinson's Disease
  - 6.2.1.3. Amyotrophic Lateral Sclerosis
  - 6.2.1.4. Huntington's Disease
  - 6.2.1.5. Other Indications
- 6.2.2. By Drug Class
  - 6.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
  - 6.2.2.2. Cholinesterase Inhibitors
  - 6.2.2.3. Dopamine Agonists
  - 6.2.2.4. Immunomodulatory Drugs
  - 6.2.2.5. Other Drug Classes
- 6.2.3. By Distribution Channel
  - 6.2.3.1. Hospital Pharmacies
  - 6.2.3.2. Retail Pharmacies
  - 6.2.3.3. Online Pharmacies
  - 6.2.3.4. Others
- 6.2.4. By Country Share
  - 6.2.4.1. United States
  - 6.2.4.2. Canada
  - 6.2.4.3. Mexico
6.3. Country Market Assessment
- 6.3.1. United States Neurodegenerative Diseases Market Outlook, 2018-2032F*
  - 6.3.1.1. Market Size Analysis & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share Analysis & Forecast
    - 6.3.1.2.1. By Indication
      - 6.3.1.2.1.1. Alzheimer's Disease
      - 6.3.1.2.1.2. Parkinson's Disease
      - 6.3.1.2.1.3. Amyotrophic Lateral Sclerosis
      - 6.3.1.2.1.4. Huntington's Disease
      - 6.3.1.2.1.5. Other Indications
    - 6.3.1.2.2. By Drug Class
      - 6.3.1.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
      - 6.3.1.2.2.2. Cholinesterase Inhibitors
      - 6.3.1.2.2.3. Dopamine Agonists
      - 6.3.1.2.2.4. Immunomodulatory Drugs
      - 6.3.1.2.2.5. Other Drug Classes
    - 6.3.1.2.3. By Distribution Channel
      - 6.3.1.2.3.1. Hospital Pharmacies
      - 6.3.1.2.3.2. Retail Pharmacies
      - 6.3.1.2.3.3. Online Pharmacies
      - 6.3.1.2.3.4. Others
- 6.3.2. Canada
- 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Neurodegenerative Diseases Market Outlook, 2018-2032F

7.1. Germany
7.2. France
7.3. Italy
7.4. United Kingdom
7.5. Russia
7.6. Netherlands
7.7. Spain
7.8. Turkey
7.9. Poland

8. Asia-Pacific Neurodegenerative Diseases Market Outlook, 2018-2032F

8.1. India
8.2. China
8.3. Japan
8.4. Australia
8.5. Vietnam
8.6. South Korea
8.7. Indonesia
8.8. Philippines

9. South America Neurodegenerative Diseases Market Outlook, 2018-2032F

9.1. Brazil
9.2. Argentina

10. Middle East and Africa Neurodegenerative Diseases Market Outlook, 2018-2032F

10.1. Saudi Arabia
10.2. UAE
10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Supply Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

17.1. Market Drivers
17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework and Innovation

19.1. Clinical Trials
19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

22.1. Competition Matrix of Top 5 Market Leaders
22.2. SWOT Analysis for Top 5 Players
22.3. Key Players Landscape for Top 10 Market Players
- 22.3.1. AbbVie Inc.
  - 22.3.1.1. Company Details
  - 22.3.1.2. Key Management Personnel
  - 22.3.1.3. Products and Services
  - 22.3.1.4. Financials (As Reported)
  - 22.3.1.5. Key Market Focus and Geographical Presence
  - 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 22.3.2. Novartis AG
- 22.3.3. Merck & Co., Inc
- 22.3.4. Biogen, Inc.
- 22.3.5. Teva Pharmaceutical Industries Ltd.
- 22.3.6. Pfizer Inc.
- 22.3.7. Sanofi S.A
- 22.3.8. GlaxoSmithKline PLC
- 22.3.9. UCB S.A.
- 22.3.10. H. Lundbeck A/S
- 22.3.11. Boehringer Ingelheim International GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

神経変性疾患の世界市場：適応症別、薬剤クラス別、流通チャネル別、地域別、機会、予測、2018年～2032年

Global Neurodegenerative Diseases Market Assessment, By Indication, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の神経変性疾患市場の見通し、2018年～2032年

第6章 北米の神経変性疾患市場の見通し、2018年～2032年

第7章 欧州の神経変性疾患市場の見通し、2018年～2032年

第8章 アジア太平洋の神経変性疾患市場の見通し、2018年～2032年

第9章 南米の神経変性疾患市場の見通し、2018年～2032年

第10章 中東・アフリカの神経変性疾患市場の見通し、2018年～2032年

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 サプライチェーン分析

第14章 ポーターのファイブフォース分析